Fig. 3: Notch3 downregulation (but not Notch1) sensitizes TNBC cells to TKI-gefitinib. | Oncogenesis

Fig. 3: Notch3 downregulation (but not Notch1) sensitizes TNBC cells to TKI-gefitinib.

From: NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest

Fig. 3

a–d Left panels: inhibition of a, b MDA-MB-468 and c, d BT-549 cell growth was observed after gefitinib (GEF) treatment combined with Notch3 silencing in a, c but not with b, d Notch1 silencing. All the right panels showed in the figure represent western blotting of total extracts from cells described above against Notch3 (N3IC) and Notch1 (N1IC), to control the efficiency of the a, c Notch3 and b, d Notch1 silencing, respectively. Anti-β-actin was used as a loading control. All data are representative of at least three independent experiments, each in triplicate. Results shown in a, b, c, and d are expressed as the means average deviations and P-values were calculated using Student’s T-test (i.e., ns not significant; P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001)

Back to article page